We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH) (RESAPH)

This study is currently recruiting participants.
Verified December 2015 by Robert P Baughman, University of Cincinnati
Sponsor:
ClinicalTrials.gov Identifier:
NCT01467791
First Posted: November 9, 2011
Last Update Posted: December 8, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
The Cleveland Clinic
Information provided by (Responsible Party):
Robert P Baughman, University of Cincinnati
November 4, 2011
November 9, 2011
December 8, 2015
November 2011
January 2017   (Final data collection date for primary outcome measure)
Survival [ Time Frame: 4 years ]
Mortality during time of study
Same as current
Complete list of historical versions of study NCT01467791 on ClinicalTrials.gov Archive Site
Disease management [ Time Frame: 4 years ]
Examine initial and follow up management
Same as current
Not Provided
Not Provided
 
Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)
Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)
Registry to follow patients with sarcoidosis associated pulmonary hypertension
This is a multi center registry of sarcoidosis associated pulmonary hypertension (SAPH). With this registry, the investigators will characterize the demographics, clinical course, hemodynamics, pulmonary physiology, and disease management of sarcoidosis associated pulmonary hypertension on the United States. The investigators will also compare these features to non-US sites.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Serum samples
Non-Probability Sample
Patients with sarcoidosis associated pulmonary hypertension
  • Sarcoidosis
  • Pulmonary Hypertension
Other: Observation
Observe patients
Patients
All patients with sarcoidosis associated pulmonary hypertension
Intervention: Other: Observation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
January 2018
January 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with sarcoidosis as defined by the ATS/WASOG statement
  • Patients with pulmonary hypertension as confirmed by right heart catheterization
  • Patients willing to provide written informed consent

Exclusion Criteria:

  • Unwillingness to provide assurance that they will complete the follow up visits for the study
Sexes Eligible for Study: All
18 Years to 100 Years   (Adult, Senior)
No
Contact: Robert P Baughman, MD 513-584-5225 bob.baughman@uc.edu
Contact: Rebecca Ingledue 513-584-6252
United States
 
 
NCT01467791
RESAPH 1
No
Not Provided
Not Provided
Robert P Baughman, University of Cincinnati
University of Cincinnati
The Cleveland Clinic
Study Chair: Robert P Baughman, MD University of Cincinnati
University of Cincinnati
December 2015